Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non‐Small Cell Lung Cancer to Receive Immunotherapy
AS Mansfield, H Dong - Clinical Pharmacology & Therapeutics, 2016 - Wiley Online Library
AS Mansfield, H Dong
Clinical Pharmacology & Therapeutics, 2016•Wiley Online LibraryThe use of programmed cell death 1 ligand 1 (PD‐L1) as a predictive biomarker to select
patients to receive programmed cell death 1 (PD‐1) or PD‐L1 inhibitors in non‐small cell
lung cancer (NSCLC) is limited by the definitions of positivity, interassay agreement, and
intra‐and intertumoral heterogeneity of expression. Although PD‐L1 expression enriches for
responses, the lack of expression does not exclude clinical benefit.
patients to receive programmed cell death 1 (PD‐1) or PD‐L1 inhibitors in non‐small cell
lung cancer (NSCLC) is limited by the definitions of positivity, interassay agreement, and
intra‐and intertumoral heterogeneity of expression. Although PD‐L1 expression enriches for
responses, the lack of expression does not exclude clinical benefit.
The use of programmed cell death 1 ligand 1 (PD‐L1) as a predictive biomarker to select patients to receive programmed cell death 1 (PD‐1) or PD‐L1 inhibitors in non‐small cell lung cancer (NSCLC) is limited by the definitions of positivity, interassay agreement, and intra‐ and intertumoral heterogeneity of expression. Although PD‐L1 expression enriches for responses, the lack of expression does not exclude clinical benefit.
Wiley Online Library